Steven C. Campbell, Brian I. Rini (eds): Renal cell carcinoma: Clinical management (Current clinical urology series), Series editor: Eric A. Klein, Humana Press, 2013, 362Dutcher · Medical Oncology2013PDF79 KB
Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active Surveillance in Metastatic Renal-cell Carcinoma: A Prospective, Phase 2 Trial. Lancet Oncol Lancet 2016;17:1317–24Capitanio · European Urology2017PDF118 KB
Re: Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022;82:427–39Zhao · European Urology2022PDF290 KB
Renal cell carcinoma. Translational biology, personalized medicine and novel therapeutic targetsEditor(s) by Robert A. Figlin, W. Kimryn Rathmell & Brian I. Rini. Published by Springer, New York, USA, 2012. 327 pp, price $189.00, ISBN: 978-1-4614-2399-7Vasudev · British Journal of Clinical Pharmacology2013PDF369 KB
Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404–15Singla · European Urology2019PDF117 KB